23 February 2017



IBA to install Spain’s first proton therapy center


Contract signed with Quirónsalud to install a Proteus®ONE solution in Madrid

Louvain-La-Neuve, Belgium, 23 February 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with Quirónsalud, Spain’s leading hospital group and part of Germany’s Helios Group, to install a Proteus®ONE* compact proton therapy solutionin Madrid.

The contract covers delivery of a Proteus®ONE solution, including latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term maintenance agreement. The hospital group will also benefit from Penn Medicine and IBA’s world leading proton therapy clinical education program. The hospital will be ready to start treating patients by 2019.

The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR 35 and 40 million. This will be IBA’s 18th installation of the compact single-room proton therapy solution.

Olivier Legrain, Chief Executive Officer of IBA, commented: “IBA’s first entry into the Spanish market demonstrates the ongoing appeal of IBA’s single room solution, Proteus®ONE. Being selected by Quirónsalud to install the first proton therapy solution in Spain, reinforces our position as the global proton therapy market leader and will bring access to the most advanced radiation therapy technology to cancer patients to this region.”

Olivier Legrain

Chief Executive Officer of IBA

“Our mission is to improve the health of patients and this can only be done by providing the highest quality health service. After the recent merger with Fresenius Helios, we are excited to partner with IBA to bring the world’s leading proton beam therapy equipment to cancer patients in Iberia for the first time. This innovative technology will enable us to ‘paint’ tumours with a super-fine beam of protons, destroying the cancer cells whilst limiting the exposure of healthy tissues surrounding the tumor and reducing the risk of secondary cancers.  At Quirónsalud, we believe that this state-of-the-art technology will also attract patients from other countries.”

Leticia Moral Iglesias

General Director of Care, Quality and Innovation of Quirónsalud group

About Proteus®ONE

Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy.

 * Proteus®ONE is the brand name of Proteus®235

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Quirónsalud and Fresenius Helios

Quirónsalud’s network is comprised of 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (“ORP”) centers located in all economically important areas in Spain. The company has about 35,000 employees and offers the full spectrum of inpatient and outpatient care. Quirónsalud was created by the merger of IDC Salud (“IDC”) and Grupo Hospitalario Quirón (“GHQ”) in 2014.

More information can be found at:  www.quironsalud.es

Fresenius Helios is the largest European private hospital operator. The Helios Group operates more than 100 proprietary clinics across Germany with a total of more than 30,000 beds, including seven maximum care clinics in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal. A majority of Fresenius Helios clinics are acute care facilities, but the company also owns post-acute care clinics. Fresenius Helios has more than 68,000 employees and treats around 4 million patients − including more than 1 million inpatients − annually.

In 2016 Fresenius Helios acquired IDC Salud Holding S.L.U. (“Quirónsalud”), Spain’s largest private hospital operator.

For further information, please contact: 

IBA
Jean-Marc Bothy
Chief Strategy Officer 
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com 

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com 

For media and investor enquiries: 

Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com


Back to previous page